The Short Answer

Hormone therapy can increase the risk of certain cancers, but the risk depends on which hormones you take, how long you take them, and your individual health history. Estrogen-progestin therapy (the combination most commonly prescribed) raises the risk of breast cancer, endometrial cancer, and ovarian cancer. Estrogen alone carries a lower breast cancer risk but a higher endometrial cancer risk. The increased risk is real but modest—it does not mean cancer will develop, and for many people the benefits of treating menopause symptoms outweigh the risks.

The good news is that the risk is not permanent. Once you stop taking hormones, your cancer risk begins to decline within months to a few years, depending on the cancer type. Understanding what the research actually shows—rather than headlines—helps you make a decision that fits your symptoms and your personal risk factors.

Key Takeaways

  • Estrogen-progestin therapy increases breast cancer risk by roughly 20 to 30 percent after five years of use, meaning the absolute risk remains low but measurably higher than in people not taking hormones.
  • Estrogen alone (without progestin) carries a lower breast cancer risk but raises endometrial cancer risk significantly unless the uterus has been removed.
  • The risk of ovarian cancer rises with hormone therapy use, though ovarian cancer itself is uncommon.
  • Risk begins to decline after you stop taking hormones, and within a few years of stopping, the excess risk largely disappears.
  • Your personal cancer risk from hormones depends on your age when you start, how long you use them, your family history, and other factors like weight and alcohol use.

What the Research Shows About Breast Cancer Risk

The largest study tracking hormone therapy and cancer is the Women's Health Initiative, which followed over 160,000 women starting in the 1990s. Women taking estrogen-progestin therapy had a 24 percent higher risk of breast cancer compared to women taking a placebo. This sounds large, but the absolute numbers matter: among 10,000 women taking estrogen-progestin for one year, about 30 would develop breast cancer compared to 24 who would develop it without the therapy. The risk climbs the longer you take hormones—five years of use carries more risk than two years.

Estrogen alone (prescribed to women without a uterus) showed a different pattern. In the same study, women taking estrogen alone for seven years had a slightly lower breast cancer risk than the placebo group, though the difference was small and not statistically significant. However, estrogen alone does carry other cancer risks, discussed below.

The type of progestin matters. Synthetic progestins (medroxyprogesterone acetate, or MPA) appear to carry higher breast cancer risk than bioidentical progestins like micronized progesterone, though the evidence is still developing. Dose and delivery method also play a role—lower doses and transdermal patches (which deliver hormones through skin) may carry lower risk than higher oral doses.

Endometrial and Ovarian Cancer Risk

Estrogen without progestin significantly increases the risk of endometrial cancer (cancer of the uterine lining). This is why women with an intact uterus are prescribed progestin alongside estrogen—the progestin protects the endometrium. Women taking estrogen-progestin together have endometrial cancer risk similar to women not taking hormones.

Ovarian cancer risk rises with hormone therapy use. The Women's Health Initiative found a 40 percent increase in ovarian cancer risk among women taking estrogen-progestin, though ovarian cancer is uncommon overall. Among 10,000 women taking estrogen-progestin for five years, roughly one additional case of ovarian cancer would occur beyond the baseline rate. The risk appears to increase with longer use and may persist even after stopping hormones.

How Risk Changes After You Stop Taking Hormones

The increased cancer risk from hormone therapy is not permanent. Studies show that breast cancer risk begins to decline within one to two years of stopping, and by five years after stopping, the excess risk largely disappears. This pattern suggests that hormones accelerate the growth of existing precancerous cells rather than creating entirely new cancer risk.

Ovarian cancer risk appears to decline more slowly after stopping, though long-term data are limited. The key point is that stopping hormone therapy reduces your cancer risk going forward, even if you took hormones for many years. This reversibility is an important part of the risk-benefit calculation when deciding whether to start hormones in the first place.

Who Has Higher Risk From Hormone Therapy

Your personal cancer risk from hormones depends on multiple factors working together. Age at start matters: women who begin hormone therapy in their 50s face different risks than those starting in their 60s or 70s. Duration of use is critical—two years carries less risk than ten years. Family history of breast cancer, current weight, alcohol consumption, and whether you have had previous breast biopsies all influence your baseline cancer risk before hormones enter the picture.

Women with a personal history of breast cancer, blood clots, or stroke should generally avoid hormone therapy because the risks outweigh the benefits. Women with a strong family history of breast cancer (multiple relatives diagnosed young) may choose to avoid hormones or use them at lower doses for shorter periods. Your doctor can discuss your individual risk profile and help you weigh the symptom relief hormones provide against your specific cancer risk.

Comparing Hormone Therapy to Other Menopause Treatments

Hormone therapy is not the only way to manage menopause symptoms. Non-hormonal medications like SSRIs (sertraline, paroxetine) and SNRIs (venlafaxine) reduce hot flashes and night sweats in many women and carry no cancer risk. Gabapentin also helps with hot flashes. These medications work more slowly than hormones and may not be as effective for severe symptoms, but they are an option for women who want to avoid hormone-related cancer risk.

Lifestyle changes—regular exercise, staying cool, avoiding triggers like alcohol and spicy foods—help some women manage symptoms without medication. The choice between hormone therapy and alternatives depends on how severe your symptoms are, how much they affect your daily life, and your personal cancer risk factors.

Understanding Your Individual Decision

The decision to use hormone therapy is personal and should be made with your doctor, not based on cancer risk alone. For a woman with severe hot flashes, night sweats that disrupt sleep, and vaginal dryness affecting quality of life, the benefit of symptom relief may outweigh a modest increase in cancer risk, especially if she uses hormones for a short time (two to three years) at the lowest effective dose. For a woman with a family history of breast cancer or a previous blood clot, the risks are less likely to justify the benefits.

The FDA recommends using hormone therapy at the lowest dose for the shortest time needed to manage symptoms. This approach reduces cancer risk while still providing relief. Regular mammograms and clinical breast exams are standard for all women over 40 and become more important if you use hormone therapy.

Frequently Asked Questions

Does bioidentical hormone therapy have lower cancer risk than synthetic hormones?

Bioidentical hormones (hormones chemically identical to those your body makes) are often marketed as safer, but the evidence is mixed. Some studies suggest bioidentical progestins carry lower breast cancer risk than synthetic ones, but large, long-term studies directly comparing them are limited. The delivery method (patch versus pill) and dose matter as much as whether hormones are bioidentical.

If I stop hormone therapy, does my cancer risk go back to normal?

Largely yes. Breast cancer risk declines within one to two years of stopping and returns to baseline within about five years. Ovarian cancer risk appears to decline more slowly. The key is that the excess risk is not permanent—it is tied to active use of the hormones.

Can I use hormone therapy if I have a family history of breast cancer?

It depends on how strong the family history is and which relatives were affected. If one relative was diagnosed after age 65, the risk may be acceptable. If multiple relatives were diagnosed before age 50, hormone therapy is usually not recommended. Your doctor can assess your inherited risk and discuss whether hormones are appropriate for you.

What is the actual number of women who develop cancer from hormone therapy?

Among 10,000 women taking estrogen-progestin for five years, roughly 6 additional breast cancers would occur beyond the expected baseline. The baseline itself varies by age and other factors, so the absolute risk is different for each person. This is why discussing your individual risk with your doctor matters more than the percentage increase.

Are there hormones that do not increase cancer risk?

No hormone therapy is risk-free, but some carry lower risk than others. Estrogen alone carries lower breast cancer risk than estrogen-progestin but higher endometrial cancer risk. Lower doses and shorter durations reduce risk. Non-hormonal medications like SSRIs and gabapentin carry no cancer risk but may not work as well for severe symptoms.